乐观
$115.59
情景价格
$89.960
+0.765 (+0.85%)收盘时
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
Merit Medical Systems Inc (MMSI) is a good buy right now due to its strong recent performance, including a 10% year-over-year revenue growth in Q2 2026, and a current price of $89.2, which is below the average analyst price target of $97. Additionally, the company has a forward P/E ratio of 18.94, indicating potential for growth relative to its earnings. However, a risk to consider is the significant insider selling, which has increased by 1341.20% over the last month, suggesting potential concerns from insiders about the stock's future performance.
BofA
$97
2026-08-12
BofA
2026-08-12
目标价
$97
Canaccord
$94
2026-08-03
Canaccord
2026-08-03
目标价
$94
BTIG
$105
2026-07-31
BTIG
2026-07-31
目标价
$105
Raymond James
$100
2026-07-31
Raymond James
2026-07-31
目标价
$100
Barrington
$114
2026-07-31
Barrington
2026-07-31
目标价
$114
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Investment Opportunities and Risks in Small-Cap Stocks

Merit Medical to Participate in Multiple Investor Conferences

Merit Medical to Participate in Investor Conferences

Merit Medical to Participate in Upcoming Investor Conferences

Merit Medical Systems Reports Strong Q2 2026 Earnings Growth
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Merit Medical Systems Inc (MMSI) is a good buy right now due to its strong recent performance, including a 10% year-over-year revenue growth in Q2 2026, and a current price of $89.2, which is below the average analyst price target of $97. Additionally, the company has a forward P/E ratio of 18.94, indicating potential for growth relative to its earnings. However, a risk to consider is the significant insider selling, which has increased by 1341.20% over the last month, suggesting potential concerns from insiders about the stock's future performance.
9 analysts cover MMSI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 104.63.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。